Patient Surveillance After Cancer Treatment (eBook)

eBook Download: PDF
2013 | 2013
XXI, 538 Seiten
Humana Press (Verlag)
978-1-60327-969-7 (ISBN)

Lese- und Medienproben

Patient Surveillance After Cancer Treatment -
Systemvoraussetzungen
213,99 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.

The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.

This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today's practicing oncologist.



Dr. Frank E. Johnson, MD
Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today's practicing oncologist.

Dr. Frank E. Johnson, MD

1. Overview David Y. Johnson and Frank E. Johnson 2. Introduction to Cancer Surveillance StrategiesBrooke Crawford and David D. Greenberg 3. Using Decision Analysis to Model Cancer SurveillanceKim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment Craig C. Earle and Jennifer Deevy 5. Upper Aerodigestive Tract Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe Béatrix Barry and Dominique De Raucourt 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada Richard W. Nason and James B. Butler 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia Leigh Delbridge 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune 12. Lung Carcinoma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson 13. Lung Carcinoma Surveillance Counterpoint: Australia Michael Boyer and Kate Mahon 14. Lung Carcinoma Surveillance Counterpoint: Japan Tokujiro Yano and Yoshihiko Maehara 15. Lung Carcinoma Surveillance Counterpoint: Canada Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans 16. Esophagus Carcinoma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson 17. Esophagus Carcinoma Surveillance Counterpoint: Australia Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister 18. Esophagus Carcinoma Surveillance Counterpoint: Japan Masaru Morita and Yoshihiko Maehara 19. Stomach Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson 20. Stomach Carcinoma Surveillance Counterpoint: USA Andrew Coleman and Douglas Tyler 21. Stomach Carcinoma Surveillance Counterpoint: Japan Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara 22. Pancreatic Adenocarcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA Tanios S. Bekaii-Saab 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe Richard A. Smith, Jane V. Butler, and John P. Neoptolemos 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan Ken Shirabe and Yoshihiko Maehara 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada Malcolm J. Moore and Anastasios Stathis 27. Liver and Biliary Tract Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe Michele Colledan 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia Michael D. Crawford 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan Akinobu Taketomi and Yoshihiko Maehara 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada Oliver F. Bathe and Kelly Warren Burak 32. Colon and Rectum CarcinomaDavid Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA Mohamedtaki A. Tejani and Steven J. Cohen 34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia Toufic El-Khoury, Michael Solomon, and Jane Young 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan Yasushi Toh and Yoshihisa Sakaguchi 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada Marko Simunovic 37. Anal Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 38. Anal Carcinoma Surveillance Counterpoint: USA Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata 39. Anal Carcinoma Surveillance Counterpoint: Australia Toufic El-Khoury, Michael Solomon, and Jane Young 40. Anal Carcinoma Surveillance Counterpoint: Japan Yoshihisa Sakaguchi and Yasushi Toh 41. Anal Carcinoma Surveillance Counterpoint: CanadaNatasha Press and John Hay 42. Soft Tissue Sarcoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA Valeriy Sedov and Janice M. Mehnert 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan Shuichi Matsuda and Yukihide Iwamoto 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada Lloyd A. Mack and Vivien H.C. Bramwell 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan Shuichi Matsuda and Yukihide Iwamoto 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada Timothy R. Asmis, Joel Werier, and Shailendra Verma 49. Cutaneous Melanoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 50. Cutaneous Melanoma Surveillance Counterpoint: USA Gerald Linette and Lynn A. Cornelius 51. Cutaneous Melanoma Surveillance Counterpoint: Australia Michael A. Henderson 52. Cutaneous Melanoma Surveillance Counterpoint: Japan Yoichi Moroi 53. Breast Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 54. Breast Carcinoma Surveillance Counterpoint: USA Kelli Pettit and Julie A. Margenthaler 55. Breast Carcinoma Surveillance Counterpoint: Europe Stefano Ciatto 56. Breast Carcinoma Surveillance Counterpoint: Australia Andrew J. Spillane and Meagan E. Brennan 57. Breast Carcinoma Surveillance Counterpoint: Japan Eriko Tokunaga and Yoshihiko Maehara 58. Endometrial Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 59. Endometrial Cancer Surveillance Counterpoint: USA Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr. 60. Endometrial Cancer Surveillance Counterpoint: USA Summer B. Dewdney and Premal H. Thaker 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan Yousuke Ueoka, Hiroaki Kobayashi, and Norio Wake 62. Endometrial Carcinoma Surveillance Counterpoint: Canada Michael Fung-Kee-Fung and Thomas K. Oliver 63. Cervical Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 64. Cervical Carcinoma Surveillance Counterpoint: USA Joshua P. Kesterson and Shashikant Lele 65. Cervical Carcinoma Surveillance Counterpoint: Japan Kenzo Sonoda, Hiroaki Kobayashi, and Norio Wake 66. Cervical Carcinoma Surveillance Counterpoint: Canada Michael Fung-Kee-Fung and Thomas K. Oliver 67. Vaginal and Vulvar Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan Shinji Ogawa, Hiroaki Kobayashi, and Norio Wake 69. Ovarian Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 70. Ovarian Carcinoma Surveillance Counterpoint: USA Maurie Markman 71. Ovarian Cancer Surveillance Counterpoint: Europe Andy Nordin 72. Ovarian Cancer Surveillance Counterpoint: Japan Hiroaki Kobayashi and Norio Wake 73. Renal CarcinomaShilpi Wadhwa, David Y. Johnson, and Frank E. Johnson 74. Renal Carcinoma Surveillance Counterpoint: Europe Alessandro Antonelli, Claudio Simeone, and Sergio Cosciani Cunico 75. Renal Carcinoma Surveillance Counterpoint: Japan Masatoshi Eto, Wataru Takahashi, Yoshiaki Kawano, Jiro Honda, Juro Nakanishi, and Yoshihiro Wada 76. Renal Carcinoma Surveillance Counterpoint: Canada Michael Leveridge, Robert Abouassaly, and Michael A.S. Jewett 77. Urinary Bladder Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan Kentaro Kuroiwa 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada Faysal A. Yafi and Wassim Kassouf 80. Prostate Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 81. Prostate Carcinoma Surveillance Counterpoint: USA Angela Smith and Raj Pruthi 82. Prostate Carcinoma Surveillance Counterpoint: USA Erik T. Goluboff and Matthew Wosnitzer 83. Prostate Carcinoma Surveillance Counterpoint: Europe Stefano Ciatto 84. Prostate Carcinoma Surveillance Counterpoint: JapanAkira Yokomizo 85. Prostate Carcinoma Surveillance Counterpoint: Canada Andrew Loblaw and Colin Tang 86. Testicle Carcinoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 87. Testicle Carcinoma Surveillance Counterpoint: USA Ian M. Thompson III and Sam S. Chang 88. Testicle Carcinoma Surveillance Counterpoint: AustraliaMichael Boyer and Kate Mahon 89. Testicle Carcinoma Surveillance Counterpoint: Japan Narihito Seki 90. Lymphoma David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 91. Lymphoma Surveillance Counterpoint: USA Kenneth R. Carson and Nancy L. Bartlett 92. Lymphoma Surveillance Counterpoint: Japan Kenjiro Kamezaki 93. Lymphoma (Following Autologous Stem Cell Transplant) Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan Toshihiro Miyamoto 95. Leukemia David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 96. Leukemia Surveillance Counterpoint: USA Olalekan Oluwole, Susan Greenhut, Bipin N. Savani, and Nishitha Reddy 97. Leukemia Surveillance Counterpoint: Japan Koji Nagafuji 98. Multiple Myeloma Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson 99. Multiple Myeloma Surveillance Counterpoint: USA Niyati Modi, G. David Roodman, and Suzanne Lentzsch 100. Multiple Myeloma Surveillance Counterpoint: Australia Liane Khoo and Douglas Joshua 101. Multiple Myeloma Surveillance Counterpoint: Japan Katsuto Takenaka 102. Multiple Myeloma Surveillance Counterpoint: Canada Matthew C. Cheung and Kevin R. Imrie 103. Glioma of the Central Nervous System David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe Wolfgang Grisold, Stefan Oberndorfer, and Eefje Sizoo 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia Margot Lehman and Michael Barton 106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan Masahiro Mizoguchi, Koji Yoshimoto, and Tomio Sasaki

Erscheint lt. Verlag 12.3.2013
Reihe/Serie Current Clinical Oncology
Zusatzinfo XXI, 538 p.
Verlagsort Totowa
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Chirurgie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizinische Fachgebiete Radiologie / Bildgebende Verfahren Radiologie
Schlagworte Breast Cancer • Cancer follow-up tests • Cancer Surveillance Tests • Colorectal Cancer • leukemia • Liver Cancer • Lung Cancer • Lymphoma • melanoma • myeloma • Pancreatic cancer • Prostate Cancer • Radiaton Oncology • Renal Cancer • surgical oncology • Thyroid Cancer • Uterine Cancer
ISBN-10 1-60327-969-5 / 1603279695
ISBN-13 978-1-60327-969-7 / 9781603279697
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 7,2 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich

von Marija Pinto

eBook Download (2023)
Urban & Fischer Verlag - Lehrbücher
26,99